Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?

Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Lorena Duca(University of Milan), Silvia Cristiani(University of Milan), Gemino Fiorelli(Ospedale Maggiore), Barbara Sarina(IRCCS Humanitas Research Hospital), Chiara Cattaneo(Humanitas University)
The Hematology Journal
January 1, 2000
10.1038/sj.thj.6200028
Cited by 72

Related Papers

Thalassaemia
|The Lancet|2017|763
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389